CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the…
| Price | $7.74 |
|---|---|
| Market cap | $606.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 6.13-13.02 |
| Beta | 1.5 |
Explore CRMD's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.